MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress

September 15-18, 2022. Madrid, Spain.

View by Title View Categories
Jump to:  View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z
  • Natural progression of patients with Parkinson disease on less pulsatile levodopa therapy

    M. Lin, R. Laureno, A. Lenka (Washington, USA)

  • Need for personalized monitoring in Parkinson’s disease: the perspectives of patients and specialized healthcare providers

    L. Evers, B. Bloem, M. Meinders (Nijmegen, Netherlands)

  • Network detection and connectivity analysis to predict DBS-induced ataxia in essential tremor

    B. Weigl, M. Reich (Würzburg, Germany)

  • Network Fingerprint of Stimulation-Induced Speech Impairment in Parkinson’s Disease

    H. Jergas, JN. Petry-Schmelzer, JG. Hannemann, T. Thies, JC. Baldermann, JN. Strelow, HS. Dafsari, D. Muecke, V. Visser-Vandewalle, TA. Dembek, MT. Barbe (Cologne, Germany)

  • Network Localisation of Multiple System Atrophy

    E. Ellis, J. Joutsa, M. Fox, D. Corp (Melbourne, Australia)

  • Neural activity during turning in Parkinson’s: influence of dual-task and freezing

    S. Stuart, R. Vitorio, J. Wagner, S. Makeig, M. Mancini (Whitley Bay, United Kingdom)

  • Neural and cognitive correlates of the co-occurrence of apathy and Impulse Control Disorder in early Parkinson’s Disease

    G. Maggi, S. Costa, F. Loayza, G. Santangelo, I. Obeso (Caserta, Italy)

  • Neural correlates of Parkinson’s disease dysgraphia

    L. Véron-Delor, M. Longcamp, JL. Anton, B. Nazarian, J. Sein, T. Witjas, S. Grimaldi, JP. Azulay, A. Eusebio, S. Pinto, J. Danna (Aix-en-Provence, France)

  • Neuroanatomical underpinnings of apathy in Parkinson’s Disease

    C. Le Heron, E. Huey, N. Vanegas-Arroyave, Y. Gazes, S. Lee (New Zealand)

  • Neurodegeneration and neuroinflammation for biomarker development in MSA

    S. Katzdobler, F. Eckenweber, G. Nübling, L. Vogler, C. Palleis, S. Lindner, U. Fietzek, B. Nuscher, A. Mueller, N. Koglin, A. Stephens, C. Haass, M. Brendel, J. Levin (Munich, Germany)

  • Neurodegeneration associated with pantothenate kinase in a Mexican Patient: Solving the Diagnostic Challenge of the Eye of Tiger

    M. Arbeu Reyes, B. Madariaga Cortés, C. Aguilar Vázquez (Mexico City, Mexico)

  • Neurofilament light chain protein (NfL) is elevated in Essential Tremor

    S. Franthal, M. Khalil, L. Pirpamer, A. Buchmann, P. Katschnig-Winter, M. Koegl-Hammer, N. Homayoon, K. Wenzel, R. Schmidt, P. Schwingenschuh (Graz, Austria)

  • Neuroimaging correlates of cognitive deficits in Wilson’s disease

    S. Shribman, M. Burrows, R. Convery, M. Bocchetta, C. Sudre, J. Acosta-Cabronero, D. Thomas, G. Gillett, E. Tsochatzis, O. Bandmann, J. Rohrer, T. Warner (London, United Kingdom)

  • Neuroimaging in Glucocerebrosidase-associated parkinsonism: a systematic review

    R. Balestrino, F. Agosta, S. Basaia, M. Filippi (Milano, Italy)

  • Neuropathological profile of tauopathy in spinocerebellar ataxia type 8

    G. Beck, Y. Yonenobu, R. Yamashita, T. Iwaki, S. Murayama, H. Mochizuki (Suita, Japan)

  • Neurophysiological and Clinical Effects of Low-intensity Transcranial Ultrasound of the Motor Cortex in Parkinson’s Disease

    T. Grippe, Y. Shamli Oghli, G. Darmani, T. Arora, C. Sarica, C. Rinchon, J. Nankoo, C. Gunraj, R. Chen (Toronto, Canada)

  • Neurophysiological Assessment of Juvenile Parkinsonism due to Primary Monoamine Neurotransmitters Disorders

    M. Passaretti, L. Pollini, G. Paparella, A. de Biase, D. Colella, S. Galosi, F. Manti, A. Guerra, V. Leuzzi, A. Berardelli, M. Bologna (Rome, Italy)

  • Neuroprotective effect of Boswellia dalzielii extracts in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

    GL. Ndji Otto, H. Adjia, JP. Mingoas Kilekoung (Bertoua, Cameroon)

  • Neuroprotective effects of estradiol and progesterone in brain of different age groups of naturally menopausal rats.: A therapeutic potential drug for Parkinson’s disease

    P. Kumar, N. Baquer (New Delhi, India)

  • Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease

    M. Sarswati, A. Gaur (Delhi, India)

  • Neuroprotective trial design methodology for Parkinson’s: a scoping review

    E. King, M-L. Zeissler, P. Sharpe, T. Boey, F. O'Brian, D. Chapman, G. Rafaloff, K. Raphael, H. Venkatesh, C. Carroll (Plymouth, United Kingdom)

  • Neuropsychological correlates of Cognitive fluctuations in dementia with Lewy bodies

    N. Dudchenko, O. Levin (Moscow, Russian Federation)

  • Neuropsychological evaluation of cerebellar cognitive function in a series of patients with genetically confirmed CANVAS.

    I. Albajar, J. Equiza, A. Lopez-de-Munain, M. Barandiaran, A. Pujol Onofre, J. Ruiz, M. Maneiro, E. Mondragon, A. Vargas, V. Velez, M. Ruiz Sales, E. Verdura Peralta, P. Iruzubieta (San Sebastian, Spain)

  • Neurovascular and immune determinants of selective vulnerability of dopaminergic neurons in Parkinson’s Disease

    T. Balzano, N. Lopez Gonzalez-Del-Rey, N. Esteban-Garcia, A. Reinares-Sebastian, I. Trigo-Damas, JA. Pineda-Pardo, C. Cavada, JA. Obeso, J. Blesa (Mostoles, Spain)

  • New-onset gait problems after bilateral STN-DBS for Parkinson’s disease: A systematic review

    J. Janssen Daalen, A. Selvaraj, D. Georgiev, B. Bloem, R. Bartels, R. Esselink, S. Vinke (Nijmegen, Netherlands)

  • New-onset Parkinsonism after Covid-19: is there a link? A 2022 report of clinical cases

    I. Boura, V. Leta, K. Rukavina, V. Raeder, C. Falup Pecurariu, M. Rodriguez-Violante, A. Antonini, K. Ray Chaudhuri (Heraklion, Greece)

  • Newly identified cases of parkinsonism and prodromal PD in a remote LRRK2 G2019S cohort

    J. Soto, S. Jensen-Roberts, T. Myers, M. Pawlik, E. Hartman, S. Lettenberger, A. Kaplan, R. Toor, R. Wilson, P. Auinger, E. Dorsey, B. Valdovinos, K. Amodeo, S. Sharma, R. Holloway, C. Tanner, R. Alcalay, R. Schneider (Rochester, USA)

  • Nicotine and influences on hyperkinetic movement disorders

    J. Qiu, L. Williams, H. Morales-Briceño, D. Olszewska, T. Lynch, V. Fung (Sydney, Australia)

  • Nigral microvasculature imaging in Parkinson’s disease

    S. Sharma, S. Buch, D. Reese, M. Haacke, M. Jog (London, Canada)

  • NIMHANS Neuropsychological Battery for Elderly in Parkinson’s disease patients: Validation and diagnosis using MDS PD-MCI task force criteria in Indian population

    R. Yadav, R. Botta, K. Kumar, BM. Kutty, A. Mahadevan, PK. Pal (Bengaluru, India)

  • No association between naturally occurring plasma tau autoantibodies and movement disorders

    AD. Magalhães, M. Emmenegger, E. de Cecco, M. Carta, K. Frontzek, A. Chincisan, S. Hornemann, A. Aguzzi (Zurich, Switzerland)

  • No evidence for the impact of SNCA rs356219 on Parkinson’s disease progression

    A. Szwedo, T. Stoker, M. Camacho, D. Backström, L. Forsgren, R. Lawson, A. Yarnall, C. Williams-Gray, A. Macleod, C. Counsell, OB. Tysnes, G. Alves, J. Maple-Grødem (Stavanger, Norway)

  • Nocturnal attacks of abnormal sleep behaviors and abnormal movements induced by insulin: A case report

    S. El-Jaafary (Cairo, Egypt)

  • Nocturnal Polyuria in Parkinson’s Disease

    M. Smith, G. Portlock, A. Cullen, M. Drake, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

  • NODDI- based maps as potential marker for Parkinson’s Disease.

    AP. Prabhu, S. Bhardwaj, A. Indoria, M. Gothwal, R. Yadav, PK. Pal, J. Saini (Bengaluru, India)

  • Non-apoptotic caspase-3 activation mediates early synaptic dysfunction of indirect pathway neurons in the parkinsonian striatum

    C. Li, T. Fieblinger, E. Espa, MA. Cenci (Lund, Sweden)

  • Non-dopaminergic system is related with motor reserve in Parkinson’s disease

    J. Youn, JH. Won, M. Kim, SH. Moon, M. Kim, JH. Ahn, YE. Huh, H. Park, JW. Cho (Seoul, Republic of Korea)

  • Non-Invasive Brain Stimulation for the Treatment of Psychiatric Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis

    Y. Qu (Wuhan, China)

  • Non-motor fluctuations in People with Parkinson’s considering Deep Brain Stimulation surgery

    T. Turner, F. Rodriguez-Porcel, C. Cooper, V. Hinson, G. Revuelta (Charleston, USA)

  • Non-motor signs in essential tremor and essential tremor-plus syndromes

    A. Nasri, A. Rekik, S. Mrabet, Y. Abida, A. Gharbi, A. Souissi, A. Gargouri, I. Kacem, R. Gouider (Mannouba, Tunisia)

  • Non-motor symptom characteristics in patients with essential tremor

    E. Jaakkola, E. Mäkinen, J. Joutsa, M. Eklund, S. Nuuttila, E. Honkanen, K. Lindholm, T. Noponen, T. Ihalainen, K. Murtomäki, T. Nojonen, R. Levo, T. Mertsalmi, F. Scheperjans, V. Kaasinen (Turku, Finland)

  • Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study

    C. Liguori, C. de Masi, M. Spanetta, M. Fernandes, R. Cerroni, E. Garasto, M. Pierantozzi, N. Mercuri, A. Stefani (Rome, Italy)

  • Non-motor symptoms in de-novo adult-onset focal dystonia

    P. Bago Rožanković, S. Lasić (Zagreb, Croatia)

  • Non-myoclonic Subacute Sclerosing Pan Encephalitis in Adulthood

    S. Garg, K. Shetty (Bengaluru, India)

  • NONINVASIVE BRAINSTEM MODULATION FOR THE TREATMENT OF NONMOTOR SYMPTOMS IN PARKINSON’S DISEASE: A RANDOMIZED CONTROLLED TRIAL AND OPEN LABEL EXTENSION STUDY

    K. Ade (Durham, USA)

  • Noninvasive focal delivery of Adeno Associated Vectors (AAV) with magnetic resonance-guided focused ultrasound in non-human primates

    J. Blesa, JA. Pineda-Pardo, K. Inoue, T. Balzano, N. Lopez Gonzalez-Del-Rey, A. Reinares-Sebastian, N. Esteban-Garcia, I. Trigo-Damas, M. Takada, JA. Obeso (MOSTOLES, Spain)

  • Novel Antipsychotics and Risk of Drug-Induced Movement Disorders and Tardive Syndromes

    G. Kannarkat, S. Caroff, J. Morley (Philadelphia, USA)

  • Novel bi-allelic variants in FBXO7 in a family with young-onset typical Parkinson’s disease

    I. Keller Sarmiento, M. Afshari, L. Kinsley, V. Silani, S. Lubbe, N. Mencacci, D. Krainc (Chicago, USA)

  • Novel insights into the genetic basis of Indian patients with Progressive supranuclear palsy (PSP)

    S. Dey, M. Debnath, R. Yelamanchi, N. Kamble, V. Holla, P. Pal, R. Yadav (Bengaluru, India)

  • Novel strategies based on sensory electrical stimulation to manage tremor in Parkinson’s disease. A pilot study.

    C. Montero Pardo, M. González Sánchez, A. Pascual Valdunciel, J. Sánchez Pérez, J. Camilo Moreno, F. Oliveira Barroso, F. Grandas, J. Luis Pons (Madrid, Spain)

  • NPC1 is not a PD risk factor gene

    G. Barrel, M. Olmedillas, K. Kandaswamy, A. Westenberger, G. Hartmann, C. Klein, P. Bauer, C. Beetz (Rostock, Germany)

  • NUS1 Mutation Causing Ataxia, Myoclonus, and Progressive Encephalopathy

    B. Barton, M. Rosenbaum (Chicago, USA)

  • Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results.

    N. Ayo (Barakaldo, Spain)

  • Nutritional Status of Patients with Parkinson’s Disease: Report from Indonesian Tertiary Referral Hospital

    SS. Musthafa, D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

Jump to:  View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley